Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Boost My Growth Hormone?
The honest map across 6 GH axis scenarios — what's been studied, where validated rhGH still rules, and which peptides have narrow FDA approval.
WHICH GH AXIS SCENARIO?
GH Context
Animal Studies
Human Trials
Confirmed adult GH deficiency (AGHD)
stimulation test confirmed
HIV-associated lipodystrophy
FDA-approved indication
Age-related somatopause
GH decline with aging
Body composition optimization
fat loss and lean mass
Sleep architecture and recovery
deep sleep GH pulses
Pediatric GH deficiency (historical)
Sermorelin prior FDA approval
Sarcopenia and elderly muscle support
MK-677 trial evidence
Adjunct after rhGH and lifestyle optimized
validated foundation first
How counts are scaled → · Tap any row to see the studies →
Quick Answer
GH axis support has well-characterized validated approaches. Foundations include endocrinologist evaluation with GH stimulation testing per Endocrine Society guidelines. Other validated approaches include FDA-approved rhGH (somatropin) for confirmed AGHD with structured IGF-1 monitoring. Additional foundations include lifestyle optimization (sleep, resistance training, body composition).
Tesamorelin anchors the GH axis peptide literature on this page through FDA approval. The compound is a stabilized GHRH(1-44) analog FDA-approved for HIV-associated lipodystrophy. Phase 3 trials reported visceral fat reduction with IGF-1 elevation. Off-label use in AGHD and body composition optimization exists.
Sermorelin is a historical GHRH(1-29) analog that previously held FDA approval for pediatric GH deficiency. The branded product (Geref) was discontinued. Compounded availability through 503A pharmacies exists for off-label adult GH axis support.
Ipamorelin / CJC-1295 is a widely-used off-label GHRP plus GHRH-analog combination. Ipamorelin is a selective ghrelin receptor agonist; CJC-1295 is a long-acting GHRH analog. The combination produces synergistic GH pulse amplification. Both are research-only in the US.
MK-677 (Ibutamoren) is an oral ghrelin receptor agonist with Phase 2/3 evidence in GH-deficient adults and elderly populations. The compound elevates GH and IGF-1 with oral administration. Research-only in the US.
The honest framing: peptide research for GH axis includes FDA-approved Tesamorelin (HIV lipodystrophy), historical Sermorelin (discontinued), Phase 2/3 MK-677, and off-label Ipamorelin/CJC-1295. Validated rhGH dominates AGHD care. For broader hormone context, see the Peptides for Hormone Optimization hub and Peptides for Testosterone Support.
Peptides vs FDA-approved rhGH (somatropin) for confirmed adult GH deficiency
Where research peptides stand against validated AGHD care
FDA-approved recombinant human growth hormone (rhGH, somatropin) has substantial evidence base for confirmed adult GH deficiency. Validated brands include Genotropin, Humatrope, Norditropin, Saizen, and Omnitrope. Endocrine Society guidelines define AGHD diagnosis through GH stimulation testing (insulin tolerance test, glucagon stimulation, or macimorelin test) plus low IGF-1 and clinical context. Treatment requires structured IGF-1 monitoring, dose titration, and ongoing endocrinologist evaluation. Required monitoring includes IGF-1 levels, glucose, lipids, and clinical symptoms.
Compared to validated rhGH, peptide research occupies different evidence positions. Tesamorelin holds FDA approval for HIV-associated lipodystrophy with Phase 3 evidence. Sermorelin had historical FDA approval for pediatric GH deficiency. MK-677 has Phase 2/3 elderly and AGHD evidence. Ipamorelin/CJC-1295 are off-label combinations.
PSI's reading: validated rhGH remains the foundation for confirmed AGHD diagnosed by stimulation testing per Endocrine Society guidelines. Tesamorelin holds the validated peptide-related role for HIV lipodystrophy. Off-label peptide use in AGHD or body composition contexts should occur within endocrinologist-directed framework with structured IGF-1 monitoring. Confirmed AGHD without rhGH treatment is not validated care.
GHRH analogs vs ghrelin receptor agonists
Two complementary GH axis stimulation pathways
GHRH analogs and ghrelin receptor agonists represent two distinct GH-stimulation pathways with complementary mechanisms. GHRH analogs (Tesamorelin, Sermorelin, CJC-1295) bind the GHRH receptor on pituitary somatotrophs producing GH pulses. Ghrelin receptor agonists (Ipamorelin, MK-677) bind GHSR-1a on somatotrophs and hypothalamic neurons producing complementary GH stimulation.
Combined administration produces synergistic pulse amplification beyond either pathway alone. The widespread off-label Ipamorelin/CJC-1295 stack leverages this synergy. The mechanism rationale is supported by basic endocrine research though confirmed-indication Phase 3 trials of the combination are absent.
PSI's reading: pulse-preserving mechanism through GHRH analogs and ghrelin agonists may have favorable safety profile compared to exogenous rhGH for select scenarios. Validated AGHD treatment remains rhGH. Off-label peptide combination use should occur within endocrinologist-directed framework with structured IGF-1 monitoring. Pulse-preserving alternatives are not equivalent substitutes for validated rhGH in confirmed AGHD.
Peptides vs lifestyle and validated foundations
Where peptides stand against validated GH axis support
Lifestyle interventions have meaningful evidence in GH axis support. Adequate sleep with deep sleep prioritization (typical GH pulse peaks during slow-wave sleep) supports endogenous GH secretion. Resistance training and high-intensity exercise stimulate GH pulses. Body fat reduction in overweight individuals improves GH axis function. Adequate protein intake and avoiding chronic caloric restriction support IGF-1. Treatment of sleep apnea, obesity, and chronic illness often improves GH axis function.
These foundations have meaningful evidence base for individuals without confirmed AGHD. Effect sizes vary by individual baseline status. The interventions are broadly available and inexpensive. Patient adherence is the dominant factor in outcomes.
Compared to lifestyle interventions, peptide research has not produced evidence supporting peptide use as substitute for these foundations in individuals without confirmed AGHD. PSI's reading: lifestyle and underlying condition optimization should be foundational. Endocrinologist evaluation should follow when foundations are optimized and AGHD is suspected. Peptide adjunct discussion should occur within validated GH axis management framework.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 4 peptides discussed for GH axis support, Tesamorelin holds FDA approval for HIV lipodystrophy with strong Phase 3 evidence. Sermorelin has historical FDA approval for pediatric GH deficiency. MK-677 has Phase 2/3 elderly trials. Ipamorelin/CJC-1295 are off-label integrative medicine combinations. Validated rhGH replacement dominates AGHD care.
Tesamorelin
Deepest current FDA-approved evidence on this page. FDA-approved for HIV lipodystrophy with Phase 3 visceral fat reduction. Off-label AGHD use exists.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Context | Animal Studies | Human Trials |
|---|---|---|
HIV-associated lipodystrophy FDA-approved indication | 6 GHRH receptor activation with GH/IGF-1 elevation in animal models. | 8 Phase 3 trials supporting FDA approval; visceral fat reduction with IGF-1 elevation. Falutz 2007, Stanley 2012 |
Adult GH axis stimulation (off-label) AGHD and body composition | 4 Pulse-preserving GH/IGF-1 elevation in animal models. | 4 Limited off-label AGHD trial data; integrative medicine clinical use. |
MK-677 (Ibutamoren)
Phase 2/3 elderly sarcopenia and AGHD evidence with sustained IGF-1 elevation. Oral administration. FDA approval not pursued; research-only.
| Context | Animal Studies | Human Trials |
|---|---|---|
Elderly sarcopenia and frailty Phase 2/3 trial evidence | 8 Sustained GH/IGF-1 elevation and lean mass effects in animal aging models. | 6 Phase 2/3 trials reporting sustained IGF-1 elevation and lean mass improvement in elderly. Nass 2008 |
Adult GH deficiency (AGHD) Phase 2 evidence | 6 GH/IGF-1 elevation in animal AGHD models. | 4 Phase 2 trials in AGHD reporting GH/IGF-1 elevation. Murphy 1998 |
Body composition (research) off-label discussion | 4 Body composition effects in animal models. | 2 Limited body composition trial data outside elderly population. |
Sermorelin
Historical FDA approval for pediatric GH deficiency (Geref discontinued). Decades of compounded clinical experience. Off-label adult use.
| Context | Animal Studies | Human Trials |
|---|---|---|
Pediatric GH deficiency (historical) prior FDA-approved indication | 8 Pulse-preserving GH release in pediatric animal models. | 12 Historical Phase 3 trials supporting FDA approval; growth response in pediatric GH deficiency. |
Adult GH axis support (off-label) compounded use | 6 Pulse-preserving GH/IGF-1 elevation in adult animal models. | 4 Limited contemporary trial data; decades of compounded clinical experience. Walker 2006 |
Ipamorelin / CJC-1295
Widely-used off-label combination with mechanism rationale and Phase 1/2 pharmacokinetic evidence. Confirmed-indication Phase 3 trials absent.
| Context | Animal Studies | Human Trials |
|---|---|---|
GH axis stimulation in healthy adults pharmacokinetic evidence | 8 Synergistic pulse-preserving GH/IGF-1 elevation with GHRP+GHRH-analog combinations. | 4 Phase 1/2 evidence supporting GH/IGF-1 elevation; confirmed-indication Phase 3 trials absent. Teichman 2006, Raun 1998 |
Body composition (off-label) integrative medicine use | 4 Body composition effects in animal GH-stimulation models. | 0 No published controlled human trials in body composition contexts. |
What's Marketed vs What's Studied
6 common claims, corrected.
“GH peptides are safer than rhGH.”
Pulse-preserving mechanism through GHRH analogs and ghrelin agonists may have theoretical safety advantages over sustained supraphysiologic rhGH levels. However, long-term safety of compounded peptides has limited characterization. Supraphysiologic IGF-1 elevation has theoretical concerns regardless of mechanism. Validated rhGH has decades of post-marketing safety data; peptide alternatives have varied data depths.
“I can boost GH with peptides instead of seeing an endocrinologist.”
Validated AGHD diagnostic workup requires GH stimulation testing per Endocrine Society guidelines. Peptide use without diagnostic workup may miss treatable pituitary conditions, mask symptoms of underlying disease, or produce unnecessary supraphysiologic GH/IGF-1. Always work with an endocrinologist for diagnosis and treatment selection.
“Tesamorelin is approved for general anti-aging.”
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Off-label use in AGHD body composition or anti-aging contexts exists but is not FDA-approved. Phase 3 development for these indications has not occurred. The compound has the most validated peptide-related GH axis evidence but within narrow FDA-approved indication.
“MK-677 is the same as growth hormone.”
MK-677 is an oral ghrelin receptor agonist that stimulates endogenous pituitary GH release. The compound is mechanistically distinct from exogenous rhGH (somatropin) which provides direct GH replacement. MK-677 effects depend on intact pituitary somatotroph function. The compounds differ substantially in mechanism, safety profile, regulatory status, and clinical use.
“Ipamorelin/CJC-1295 will reverse aging.”
Ipamorelin/CJC-1295 produces GH/IGF-1 elevation through synergistic pulse amplification. Whether this elevation produces meaningful clinical benefits in healthy aging adults beyond what lifestyle interventions provide is not established by Phase 3 trials. Research-grade adjunct discussion may have a role under endocrinologist guidance but should not be presented as anti-aging therapy.
“I should self-prescribe GH peptides from research chemical sources.”
Self-administration of GH-releasing peptides without diagnostic workup, monitoring, and prescription oversight is unsafe. Risks include masking conditions, supraphysiologic IGF-1 with theoretical cancer concern, glucose intolerance with MK-677, edema, and product purity issues. Always work with a licensed endocrinologist or men's health specialist.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get GH stimulation testing before peptide consideration for AGHD.
Validated AGHD diagnosis requires GH stimulation testing (insulin tolerance test, glucagon stimulation, or macimorelin test) per Endocrine Society guidelines. IGF-1 alone is insufficient. Self-treatment without diagnostic workup is not evidence-based GH axis care.
Work with endocrinologist for AGHD or integrative medicine for off-label use.
AGHD management requires endocrinologist evaluation, treatment selection, and structured IGF-1 monitoring. Off-label peptide use can occur with integrative medicine but should ideally be coordinated with or referred for endocrinologist evaluation.
Consider FDA-approved options for your scenario.
FDA-approved rhGH (somatropin) is validated for confirmed AGHD. Tesamorelin is FDA-approved for HIV-associated lipodystrophy. These should be considered before off-label peptide use when clinically appropriate.
Verify WADA prohibited-list status if subject to testing.
WADA prohibits all GH-releasing peptides at all times. This includes GHRH analogs (Tesamorelin, Sermorelin, CJC-1295), GHRPs (Ipamorelin), and oral ghrelin agonists (MK-677). Athletes cannot use these compounds regardless of US legal status.
Compounded peptides require physician prescription and licensed pharmacy.
503A pharmacies prepare patient-specific compounds; 503B outsourcing facilities prepare office-use stock. Demand third-party HPLC purity testing and certificates of analysis. Avoid research-chemical sources.
Track IGF-1 and clinical markers, not just subjective sense of effect.
Validated monitoring includes baseline and follow-up IGF-1 levels, glucose, lipids, and clinical symptoms. Supraphysiologic IGF-1 has theoretical concerns and warrants dose adjustment. Objective progression should align with subjective improvement; if not, reassess with specialist.
The regulatory landscape for GH axis peptides is dynamic. Tesamorelin remains FDA-approved with established commercial product. Sermorelin branded product remains discontinued; compounded availability continues. MK-677 development was paused; research-only status persists. WADA prohibited list updates annually with all GH-releasing peptides remaining prohibited. Endocrine Society and AACE guidelines for AGHD diagnostic and treatment frameworks continue evolving. FDA compounding decisions affect 503A and 503B availability of GH peptides. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Are any GH axis peptides FDA-approved?
Tesamorelin is FDA-approved for HIV-associated lipodystrophy as Egrifta SV. Sermorelin previously held FDA approval for pediatric GH deficiency (Geref) but the branded product was discontinued. MK-677 has Phase 2/3 evidence but FDA approval was not pursued. Ipamorelin and CJC-1295 are research-only. None except Tesamorelin (HIV lipodystrophy) is currently FDA-approved for any indication. Validated rhGH (somatropin) remains the foundation for confirmed adult GH deficiency.
What is the validated diagnostic workup for adult GH deficiency?
Endocrine Society guidelines define adult GH deficiency through GH stimulation testing including insulin tolerance test (gold standard but contraindicated in many patients), glucagon stimulation test, or macimorelin test. IGF-1 level alone is not sufficient for AGHD diagnosis. Required clinical context includes pituitary disease history, hypopituitarism, or transitional pediatric GHD continuing into adulthood. Treatment with rhGH should follow confirmed AGHD diagnosis with structured IGF-1 monitoring.
Should I tell my doctor if I want to use GH peptides?
Yes. Tell your endocrinologist about any GH peptide use, planned or current. GH axis management requires diagnostic workup, treatment selection, and structured IGF-1 monitoring. Peptide use without specialist oversight can mask conditions, produce supraphysiologic IGF-1 with theoretical concerns, and interact with other treatments. Specialist coordination is essential.
Does Tesamorelin actually boost growth hormone?
Tesamorelin is a stabilized GHRH(1-44) analog that stimulates pituitary GH release through GHRH receptor activation. Phase 3 trials in HIV-associated lipodystrophy reported visceral fat reduction with IGF-1 elevation. The compound is FDA-approved for HIV lipodystrophy. Off-label use in AGHD and body composition optimization exists. The mechanism preserves physiologic GH pulse architecture unlike exogenous rhGH.
What is the difference between Sermorelin and Tesamorelin?
Both are GHRH analogs that stimulate pituitary GH release. Sermorelin is GHRH(1-29), the biologically active fragment. Tesamorelin is stabilized GHRH(1-44) with N-terminal modification extending half-life. Tesamorelin holds current FDA approval (HIV lipodystrophy); Sermorelin's branded product was discontinued. Compounded Sermorelin is widely used off-label. Tesamorelin has more current evidence; Sermorelin has decades of compounded experience and favorable cost.
Why is Ipamorelin combined with CJC-1295?
The combination leverages two complementary GH-stimulation pathways. Ipamorelin is a selective ghrelin receptor agonist (GHSR-1a). CJC-1295 is a long-acting GHRH analog. The pathways synergize to produce amplified pulse-preserving GH release beyond either alone. The mechanism rationale is supported by basic endocrine research. Confirmed-indication Phase 3 trials of the combination are absent. Use is research-only in the US with widespread off-label integrative medicine adoption.
Is MK-677 safe for long-term use?
MK-677 has Phase 2/3 evidence including 1-year elderly trials. Side effects include increased appetite, mild edema, and mild glucose elevation in some patients. Long-term safety beyond trial duration has limited characterization. Theoretical concerns include sustained IGF-1 elevation effects on insulin sensitivity and cancer risk. FDA approval was not pursued despite favorable efficacy data. Use should occur with endocrinologist guidance and IGF-1 monitoring.
Are these peptides legal in the United States?
Tesamorelin is FDA-approved (Egrifta) and available by prescription. Sermorelin is available through compounded pathways (503A pharmacies) following Geref discontinuation. Ipamorelin, CJC-1295, and MK-677 are research-only with limited compounded availability. WADA prohibits all GH-releasing peptides for athletes subject to testing. Always work with a licensed prescriber within validated medical framework.
Can lifestyle changes raise GH enough to avoid peptides?
Lifestyle interventions have meaningful evidence in GH axis support for individuals without confirmed AGHD. Adequate sleep with deep sleep prioritization, resistance training and high-intensity exercise, body fat reduction, adequate protein intake, and treatment of sleep apnea all support endogenous GH secretion. Effect sizes vary. For individuals without confirmed AGHD, lifestyle optimization should be foundational. For confirmed AGHD, validated rhGH treatment is appropriate.
What are common side effects of GH peptides?
Common side effects include injection site reactions (subcutaneous peptides), mild fluid retention, increased appetite (particularly MK-677), mild glucose elevation, and rarely arthralgia. IGF-1 elevation requires monitoring. Theoretical concerns include long-term effects of supraphysiologic IGF-1 on insulin sensitivity and cancer risk. Tesamorelin Phase 3 safety data is favorable in HIV lipodystrophy population. Compounded products add purity concerns.
What questions should I ask a doctor about GH peptides?
Ask: (1) Is my AGHD diagnosis confirmed by GH stimulation testing per Endocrine Society guidelines? (2) Is rhGH (somatropin) appropriate for my situation as validated first-line therapy? (3) For the peptide being considered, what evidence supports its use in my specific scenario? (4) What IGF-1 monitoring will I need and how often? (5) Are there glucose, edema, or appetite considerations specific to the peptide? (6) Are compounded formulations from a state-licensed pharmacy with third-party testing? (7) What are the long-term safety considerations including theoretical IGF-1 concerns?
What is the difference between GH peptides and rhGH (somatropin)?
Recombinant human growth hormone (rhGH, somatropin) is direct exogenous GH replacement that produces sustained supraphysiologic levels and suppresses endogenous GH pulses. GHRH analogs (Tesamorelin, Sermorelin, CJC-1295) and ghrelin receptor agonists (Ipamorelin, MK-677) stimulate endogenous pituitary GH release with preserved pulse architecture and feedback regulation. rhGH is FDA-approved for AGHD with substantial evidence. Pulse-preserving peptides have specific roles within validated framework.
Are GH peptides safer for cancer risk than rhGH?
IGF-1 elevation has theoretical association with cancer risk regardless of stimulation mechanism. Validated rhGH for confirmed AGHD has decades of post-marketing safety data including cancer surveillance. Pulse-preserving peptides have limited long-term cancer surveillance data. The honest framing: theoretical IGF-1 concerns apply to all GH axis stimulation; validated rhGH has best-characterized long-term cancer surveillance; peptide alternatives have varied data depths.
What lifestyle changes have stronger evidence than GH peptides?
Several lifestyle changes have meaningful evidence for GH axis support in individuals without confirmed AGHD. Adequate sleep with deep sleep prioritization (typical GH peaks during slow-wave sleep). Resistance training and high-intensity exercise stimulate GH pulses. Body fat reduction in overweight individuals improves GH axis function. Adequate protein intake and avoiding chronic caloric restriction support IGF-1. Treatment of sleep apnea often improves GH axis function. These should be optimized before peptide consideration.
Should I work with endocrinology or integrative medicine for GH support?
Endocrinology provides comprehensive AGHD diagnostic workup, pituitary evaluation, and validated rhGH treatment. Integrative medicine and men's health practices often manage off-label peptide protocols. The right specialist depends on clinical scenario. Endocrinologist evaluation is appropriate for AGHD diagnosis, suspected pituitary dysfunction, and validated rhGH consideration. Off-label peptide discussion can occur with integrative medicine but should ideally be coordinated with or referred for endocrinologist evaluation.
How long does it take to see effects from GH peptides?
Initial GH and IGF-1 elevation occurs within hours to days of starting therapy. Body composition effects (visceral fat reduction in Tesamorelin trials, lean mass effects in MK-677 elderly trials) typically require 3-6 months of treatment. Sleep architecture effects may be noticed within weeks. Effect magnitude varies substantially by individual baseline status and clinical context. Realistic expectations should align with trial-validated effect sizes within clinical context.
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.